Digestive Diseases and Sciences

, Volume 27, Issue 12, pp 1063–1066 | Cite as

Effect of an oral beta2-adrenergic agonist on lower esophageal sphincter pressure in normals and in patients with achalasia

  • Anthony J. DiMarinoJr
  • Sidney Cohen
Original Articles


The effect of the beta2-adrenergic agonist, carbuterol, was studied on the lower esophageal sphincter (LES) pressure in normals and in patients with achalasia. In normals, the mean LES pressure decreased from 23.1±6.2 mm Hg (mean±sem) to 16.0±5.0 mm Hg at a 4.0-mg dose of carbuterol (P<0.05). In patients with achalasia, the mean LES pressure decreased from 50.1±5.1 mm Hg to 22.7±2.4 mm Hg after a 4.0-mg dose of carbuterol (P<0.01). The duration of action following oral administration exceeded 90 min. These studies indicate that the LES in man has beta2-adrenergic receptors that mediate a reduction in pressure. The magnitude of LES pressure reduction in patients with achalasia suggests that this drug may be of therapeutic benefit.


Public Health Oral Administration Therapeutic Benefit Achalasia Lower Esophageal Sphincter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Christensen J: Pharmacological identification of lower esophageal sphincter. J Clin Invest 49:681–691, 1970PubMedGoogle Scholar
  2. 2.
    Goyal RK, Rattan S: Genesis of basal sphincter pressure: Effect of tetrodotoxin on lower esophageal sphincter pressure in opposumin vivo. Gastroenterology 71:62–67, 1976PubMedGoogle Scholar
  3. 3.
    Carlson AJ, Boyd TE, Pearcy JF: Studies on the visceral sensory end of the esophagus in mammals. Am J Physiol 61:14–41, 1922Google Scholar
  4. 4.
    Clark CG, Vane JR: The cardiac sphincter in the cat. Gut 2:252–262, 1961PubMedGoogle Scholar
  5. 5.
    Goyal RK, Rattan S: Mechanism of lower esophageal sphincter relaxation: Action of prostaglandin E1 and theophyllin. J Clin Invest 52:237–241, 1973Google Scholar
  6. 6.
    Schenck EA, Frederickson EL: Pharmacologic evidence for a cardiac sphincter mechanism in the cat. Gastroenterology 40:75–80, 1961PubMedGoogle Scholar
  7. 7.
    Christensen J, Daniel EE: Effect of some autonomic drugs on circular esophageal smooth muscle. J Pharmacol Exp Ther 159:243–249, 1968PubMedGoogle Scholar
  8. 8.
    Christensen J, Dons RF: Regional variations in responses of cat esophageal muscle to stimulation with drugs. J Pharmacol Exp Ther 161:55–58, 1968PubMedGoogle Scholar
  9. 9.
    Ellis FG, Kauntze R, Trounce JR: The innervation of the cardia and lower esophagus in man. Br J Surg 47:466–472, 1960PubMedGoogle Scholar
  10. 10.
    Carlson AJ, Litt S: Studies on the visceral sensory nervous system. Am J Physiol 65:534–536, 1923Google Scholar
  11. 11.
    Lehman G: Gastric cardiospasm in the dog. Am J Physiol 143:163–168, 1945Google Scholar
  12. 12.
    DiMarino AJ, Cohen S: The adrenergic control of lower esophageal sphincter function: An experimental model of denervation sensitivity. J Clin Invest 52:2264–2271, 1973PubMedGoogle Scholar
  13. 13.
    Smith MI: The action of the autonomic drugs on the surviving stomach. Am J Physiol 46:232–243, 1918Google Scholar
  14. 14.
    Doody PT: Adrenergic modulation of vagal inhibitory action: Evidence for dopamine receptors. Gastroenterology 70:139, 1976 (abstract)Google Scholar
  15. 15.
    Vizi ES: The role of alpha-adrenoreceptors situated in Auerbach's plexus in the inhibition of gastrointestinal motility.In Physiology of Smooth Muscle. E Bulbring, MF Shuka (eds). New York, Raven Press, 1976, pp 357–367Google Scholar
  16. 16.
    DiMarino AJ, Cohen S: The adrenergic control of lower esophageal sphincter function: response to the beta-adrenergic agonists. Proc Soc Exp Biol Med 148:1265–1269, 1975PubMedGoogle Scholar
  17. 17.
    Hinda L, Katz RL: Dissociation of tracheobronchial and cardiac effects on some beta-adrenergic stimulants. Anesthesiology 34:445–449, 1971PubMedGoogle Scholar
  18. 18.
    Furchgott RD: The classification of adrenoreceptors (adrenergic receptors): An evaluation from standpoint of receptor theory.In Catecholamines. H Blaschko, E Muscholl (eds). New York, Springer-Verlag, 1972, pp 283–332Google Scholar
  19. 19.
    Goyal RK, Rattan S: Neurohumoral, hormonal and drug receptors for the lower esophageal sphincter. Gastroenterology 74:598–619, 1978PubMedGoogle Scholar
  20. 20.
    Mukhopadkyay AK: Idiopathic lower esophageal sphincter incompetence and esophageal stricture. Arch Intern Med 140:1493–1499, 1980PubMedGoogle Scholar
  21. 21.
    DiMarino AJ, Cohen S: Characteristics of lower esophageal sphincter function in symptomatic diffuse esophageal spasm. Gastroenterology 66:1–6, 1974PubMedGoogle Scholar
  22. 22.
    Lands AM, Brown TR Jr: A comparison of the cardiac stimulating and bronchodilator actions of selected sympatho-mimetic amines. Proc Soc Exp Biol Med 116:331–333, 1964PubMedGoogle Scholar
  23. 23.
    Lands AM, Arnold A, McAuliff, JP, Lundena FP, Brown TG Jr: Differentiation of receptor systems activated by sympatho-mimetic amines. Nature 214:597, 1967PubMedGoogle Scholar
  24. 24.
    Lands AM, Ludena FP, Buzzo HJ: Differentiation of receptors response to isoproterenol. Life Sci 6:2241–2249, 1967PubMedGoogle Scholar
  25. 25.
    Mukhopadhyay A, Rattan S, Goyal RK: Effect of prostaglandin E2 on esophageal motility in man. J Appl Physiol 39:478–481, 1975Google Scholar
  26. 26.
    Goyal RK, Mukhopadhyay A, Rattan S: Effect of prostaglandin E2 on the lower esophageal sphincter in normal subjects and patients with achalasia. Clin Res 22:358, 1974 (abstract)Google Scholar
  27. 27.
    Dilawari JB, Newman A, Poleo J, Misciewisz JJ: Response of the human cardiac sphincter to circulating prostaglandins F2 and E2 and to antiinflammatory drugs. Gut 16:137–143, 1975PubMedGoogle Scholar
  28. 28.
    Dodds WJ, Dent J, Hogan WJ, Patel G, Toouli J, Arndorfer RC: Paradoxical lower esophageal sphincter contraction induced by cholecystokinin-octapeptide in patients with achalasia. Gastroenterology 80:327–333, 1981PubMedGoogle Scholar
  29. 29.
    Bortolotti M, Labo T: Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 80:39–44, 1981PubMedGoogle Scholar
  30. 30.
    Lobis IF, Fisher RS: Anticholinergic therapy for achalasia: A controlled trial. Gastroenterology 70:976, 1976Google Scholar

Copyright information

© Digestive Disease Systems, Inc. 1982

Authors and Affiliations

  • Anthony J. DiMarinoJr
    • 1
  • Sidney Cohen
    • 1
  1. 1.Gastrointestinal Section, Department of MedicineUniversity of Pennsylvania at the Hospital of the University of PennsylvaniaPhiladelphia

Personalised recommendations